Please login to the form below

Not currently logged in

BMS and AZ gain approval for diabetes drug

The European Commission has granted marketing authorisation for Onglyza throughout the EU

The European Commission has granted marketing authorisation for the diabetes treatment Onglyza (saxagliptin) throughout the European Union(EU).

The once-daily 5 mg oral tablet dose is indicated in adult patients with type 2 diabetes mellitus in combination with other therapies (metformin, sulphonylurea, or thiazolidinedione) subject to certain criteria.

It was developed by Bristol-Myers Squibb(B-MS) and AstraZeneca(AZ) and is the first drug to be launched in Europe as part of the ongoing R&D collaboration between the two companies.

Béatrice Cazala, Bristol-Myers Squibb's president, Europe, and president, global commercialization, said: "The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca."

Ulf Sather, AstraZeneca's regional vice president for Europe, commented: "Today's announcement is good news for those affected by type 2 diabetes and further demonstrates the commitment of AstraZeneca and Bristol-Myers Squibb to bring much needed options for the treatment of type 2 diabetes."

6th October 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Haseeb Ahmad
Can value-based healthcare take off and reach for the skies?
Are companies willing to contribute to the change in the healthcare system?...
Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...